This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q80.1 / Special Copayment Reduction: V300 / Re-certification cycle: 5 years |
| B. Synonyms | X-linked ichthyosis; steroid sulfatase deficiency |
| C. Adult onset | Onset in the neonatal period or early infancy; chronic disease persisting throughout life |
| 1. History | Wells & Kerr (1966) established X-linked inheritance; Shapiro (1978) identified the STS gene |
| 2. Causes | Deletion or point mutation of the STS (steroid sulfatase) gene on the short arm of the X chromosome |
| 3. Genetics | X-linked recessive; STS gene at Xp22.3; large deletion in about 90% |
| 4. Epidemiology | Prevalence in males about 1/2,000-6,000; occurs in all ethnic groups |
| 5. Pathophysiology | STS enzyme deficiency → accumulation of cholesterol sulfate in the stratum corneum → impaired desquamation → scale formation |
| 6. Symptoms | Brown-black scaling, generalized dryness, pruritus, corneal opacity (adult males) |
| 7. Signs | Brown scaling of the neck, trunk, and extensor surfaces of the limbs; corneal opacity on slit-lamp examination |
| 8. Screening | Measurement of STS enzyme activity in serum or dried blood spots; prenatal testing |
| 9. Diagnosis | STS enzyme activity + confirmation of STS gene deletion by FISH or MLPA |
| 10. Treatment | No curative treatment; moisturizers, keratolytic agents (urea, salicylic acid, retinoids) |
| 11. Prognosis | Normal lifespan; skin symptoms persist for life; additional phenotypes with contiguous gene deletions |
| 12. Prevention | Fundamental prevention not possible; genetic counseling, prenatal testing of carriers, prevention of complications through skin care |
| 13. References | Hernandez-Martin A et al. X-linked ichthyosis: an update. and 9 other papers |
X-linked ichthyosis (XLI) is the second most common hereditary disorder of skin keratinization among the ichthyoses, after ichthyosis vulgaris. The term ichthyosis itself derives from the Greek 'ichthys' (fish), reflecting the resemblance of the scaly skin to fish scales. The first systematic clinical descriptions of ichthyosis go back to the 18th century, but X-linked ichthyosis was recognized as an independent entity in the mid-20th century.
In 1966, Wells and Kerr analyzed pedigrees of ichthyosis patients and demonstrated that a particular phenotype follows X-linked recessive inheritance, thereby establishing X-linked ichthyosis as a distinct disease separate from ichthyosis vulgaris, which follows autosomal dominant inheritance. In the 1970s, several investigators including Koppe, Seip, and Shapiro found markedly elevated serum and skin cholesterol sulfate concentrations in patients with X-linked ichthyosis. In 1978, Shapiro et al. first demonstrated deficient steroid sulfatase (STS) activity in leukocytes and skin fibroblasts, establishing deficiency of this enzyme as the biochemical cause of X-linked ichthyosis.
In the 1980s-1990s, when molecular genetic approaches became available, the STS gene was found to be located at Xp22.3 on the short arm of the X chromosome, and a large deletion encompassing the STS gene was identified as the cause in about 90% of patients. This deletion can be detected by fluorescence in situ hybridization (FISH) or multiplex ligation-dependent probe amplification (MLPA). From the 1990s onward, non-allelic homologous recombination (NAHR) between sulfatase pseudogenes located at the boundaries of the STS gene deletion was shown to be the main mechanism of the large deletion. From the 2000s onward, in some contiguous gene deletion cases, additional phenotypes due to simultaneous deletion of neighboring genes near the STS gene such as KAL1, VCX, and NLGN4X (Kallmann syndrome, cognitive impairment, etc.) were identified, making the clinical heterogeneity clearer.
The cause of X-linked ichthyosis is a loss-of-function variant of the STS (steroid sulfatase) gene located at Xp22.3 on the short arm of the X chromosome. The STS gene is about 146 kb in full length and consists of 10 exons. The steroid sulfatase encoded by this gene (STS, EC 3.1.6.2) is an enzyme located in the membrane of the endoplasmic reticulum and catalyzes the removal of the sulfate group from sulfated steroids. In the skin, the main substrate of STS is cholesterol sulfate (CS), and STS mediates its conversion to cholesterol.
In about 85-90% of all X-linked ichthyosis patients, the cause is a large deletion that includes all or most of the STS gene. The size of this deletion is usually about 1.5-2.5 Mb, and it arises by non-allelic homologous recombination between the sulfatase pseudogenes (STSP1, STSP2) flanking the STS gene on both sides. In the remaining 10-15% of patients, the cause is a point mutation or a small deletion/insertion. Point mutation types include missense variants, nonsense variants, splice site variants, and frameshift variants. Compared with large deletions, point mutation cases do not show clearly distinct clinical phenotype differences, but a relatively mild phenotype has been reported in some splicing variants. The size and boundaries of the STS gene deletion determine whether neighboring genes are deleted at the same time, in which case additional phenotypes may appear as a contiguous gene deletion syndrome.
X-linked ichthyosis follows an X-linked recessive mode of inheritance. The STS gene is located at Xp22.3, adjacent to the pseudoautosomal region (PAR1) of the short arm of the X chromosome, and this positional characteristic has important implications for genetic analysis. Males (46,XY) have only one normal X chromosome and are therefore hemizygous, showing full clinical expression with only one defective copy of the STS gene. Therefore X-linked ichthyosis manifests almost exclusively in males.
Females (46,XX) become carriers if only one of the two X chromosomes is defective, and generally show no clinical symptoms. The reason is that the STS gene on the opposite normal X chromosome compensates for the function. However, when X-inactivation is severely skewed, mild skin symptoms may appear in some female carriers. In addition, in Turner syndrome (45,X), clinical expression is possible even in females if the single X chromosome carries an STS deletion. In analysis of inheritance patterns, the mother of an affected male is generally a carrier and transmits it to her sons with 50% probability. All daughters of an affected male become obligate carriers. De novo mutations also occur, in which case the mother is not a carrier. For molecular diagnosis, detection of deletions using FISH, MLPA, or array CGH is standard, and if no deletion is detected, point mutations are identified by full-length sequencing of the STS gene. Carrier testing can be offered to female relatives on the maternal side, enabling genetic counseling before childbirth.
X-linked ichthyosis is the second most common type of ichthyosis after ichthyosis vulgaris, and its prevalence is relatively well established. The prevalence in males is reported as about 1/2,000-1/6,000 depending on ethnicity, about 1/2,000-1/4,000 in Western European populations, and a similar or slightly lower frequency in Asian and African populations. In females, carriers rarely show clinical symptoms and are therefore often excluded from actual clinical prevalence, but the prevalence of STS deletion carriers is about twice that of male patients.
Variation in prevalence by region and ethnicity has been reported, but it occurs in all ethnic groups, and a founder effect in specific groups has been reported in some cases. The frequency in East Asian populations including Korea is estimated to be similar to or slightly lower than in Europe. In sex distribution, clinical patients are almost exclusively male, and females are clinically diagnosed only rarely when carriers show mild symptoms. By age, skin symptoms begin in the neonatal period or early infancy, but when symptoms are mild, some patients are first diagnosed at school age or in adulthood. Worldwide, X-linked ichthyosis is classified as a rare disease, and in Korea it is also designated as a Special Copayment Reduction (V300) disease, so medical expense support is provided.
The pathophysiology of X-linked ichthyosis centers on accumulation of cholesterol sulfate in the stratum corneum of the skin due to STS enzyme deficiency and the resulting impairment of stratum corneum desquamation.
In normal skin homeostasis, STS is expressed in keratinocytes and sebaceous glands and catalyzes the conversion of cholesterol sulfate (CS) to cholesterol. Cholesterol sulfate is present in small amounts as a component of the intercellular lipid layer of the stratum corneum and plays a role in inhibiting the activity of the serine proteases KLK5 (kallikrein-5) and KLK7 (kallikrein-7). These serine proteases degrade corneodesmosin and desmoglein-1, the main components of corneodesmosomes, thereby inducing desquamation of the stratum corneum. Therefore, normally, as cholesterol sulfate is converted to cholesterol and decreases while moving toward the skin surface, KLK5/KLK7 become activated and desquamation of the stratum corneum occurs.
In STS deficiency, cholesterol sulfate cannot be degraded and accumulates in the stratum corneum, so inhibition of KLK5/KLK7 persists. As a result, corneodesmosomes are not degraded, intercorneocyte bonds are excessively maintained, desquamation of the stratum corneum is delayed, and abnormally thick scales are formed. This is the direct pathogenesis of the thick brown scales that are the clinical phenotype of ichthyosis. Cholesterol sulfate in the stratum corneum also affects the water barrier function, causing increased transepidermal water loss (TEWL) and skin dryness. STS is also expressed in the cornea, and in deficiency cholesterol sulfate is deposited in the corneal epithelium and the entire stroma, causing corneal opacity. Corneal opacity detectable on slit-lamp examination occurs in about 50% of adult males, but it generally does not affect vision.
The clinical symptoms of X-linked ichthyosis are mainly confined to the skin, and in most patients skin symptoms are the only clinical manifestation. However, depending on the extent of the large deletion encompassing the STS gene, additional symptoms due to deletion of neighboring genes may accompany it.
Skin symptoms begin in the neonatal period or early infancy and follow a chronic course persisting throughout life. In the neonatal period they begin as fine scaling over the whole body and develop over several weeks to months into the characteristic large, plate-like brown to dark brown scales. The mainly affected sites are the neck, sides of the trunk, and extensor surfaces of the limbs (especially the anterior shin), while the flexural areas (inside of the elbows, popliteal fossa) have relatively little scaling. The scalp, forehead, and back of the auricles are also commonly affected. Importantly, in X-linked ichthyosis the palms and soles are generally not affected, which is one of the points of differentiation from ichthyosis vulgaris. The face is also generally not involved or only mildly involved. Pruritus (itching) varies among patients but is generally mild compared with ichthyosis vulgaris. Skin dryness is persistently present and worsens in low-humidity environments or in winter. Corneal opacity occurs in about 50% of adult males, appears as grayish-white punctate deposits throughout the full thickness of the cornea, and is found on slit-lamp examination. Visual loss generally does not occur. In contiguous gene deletion cases, Kallmann syndrome (KAL1 deletion, hyposmia and hypogonadism), intellectual disability, autism spectrum disorder, and so on may accompany. Prenatally, delayed labor onset may occur in the mother due to accumulation of cholesterol sulfate, so obstetric attention is needed.
The clinical signs of X-linked ichthyosis are identified through physical examination and ophthalmic examination. The combination of characteristic physical examination findings and ophthalmic findings strongly suggests the diagnosis.
As skin signs, large, thick, brown to dark brown plate-like scales on the neck, sides of the trunk, and extensor surfaces of the limbs are most characteristic. Unlike the fine grayish-white scales of ichthyosis vulgaris, the scales have a distinct brown or dark brown color, which is sometimes described as "dirty-looking skin." The skin beneath the scales shows normal skin color without hyperpigmentation, and removing the scales exposes a smooth skin surface. The skin is not thin and does not have reduced tensile strength, and there are no abnormal blisters or erosions. There is almost no scaling in the flexural areas and face (including the eyelids), which distinguishes it from ichthyosis vulgaris. The scalp has moderate scaling, and alopecia does not accompany it. As ophthalmic signs, slit-lamp biomicroscopy shows grayish-white punctate or needle-like opacities throughout the full thickness of the cornea. This corneal opacity is found in about 50% of adult males and about 25-30% of female carriers, and its prevalence tends to increase with age. Corneal opacity generally does not affect vision, but mild visual loss has rarely been reported in extensive cases. A silvery-gray scaly color change of the scrotum is observed in some patients. In contiguous gene deletion cases, hyposmia or anosmia on olfactory testing and physical findings of hypogonadism (small testes, cryptorchidism) may accompany.
Screening tests for X-linked ichthyosis are divided into enzyme activity measurement and prenatal screening methods. It is often not yet included in national newborn screening programs, but when clinically suspected, prompt enzyme testing can hasten diagnosis.
Measurement of STS enzyme activity is the first biochemical screening test performed in patients with clinical suspicion. Peripheral blood leukocytes, skin fibroblasts, or dried blood spots (DBS) can be used as specimens. In patients with an STS gene deletion, STS enzyme activity is unmeasurable or markedly reduced to less than 1% of controls. The method using dried blood spots is suitable for newborn screening and is efficient when combined with a multi-enzyme screening method. Enzyme activity measurement gives a positive result through loss of enzyme activity not only in large deletions but also in cases due to point mutations. Measurement of plasma or skin cholesterol sulfate concentration can also be used as an adjunct to biochemical diagnosis, and a 10- to 50-fold elevation over normal appears in patients. Prenatal screening can be performed when a carrier woman is pregnant. A marked decrease may appear in maternal serum unconjugated estriol (uE3), which is due to placental STS deficiency. If decreased maternal serum uE3 is confirmed, fetal genetic testing (detection of STS deletion using DNA from amniotic cells or chorionic villus biopsy) is performed. When there is a family history, preimplantation genetic testing (PGT) can also be considered.
The diagnosis of X-linked ichthyosis is made by integrating three elements: clinical findings, biochemical testing (measurement of STS enzyme activity), and molecular genetic testing (confirmation of STS gene deletion).
Clinical diagnosis can be strongly suspected from characteristic brown plate-like scales beginning in the neonatal period or early infancy, distribution predominantly on the neck and sides of the trunk, sparing of the palms and soles, corneal opacity in adult males, and an X-linked recessive family history (ichthyosis in maternal male relatives). For biochemical testing, measurement of STS enzyme activity in peripheral blood leukocytes is the standard. In patients with an STS deletion, activity is almost unmeasurable at 0-1% of normal. Measurement of STS activity after skin fibroblast culture is also possible. For molecular genetic testing, confirmation of an Xp22.3 deletion using FISH has traditionally been used, but MLPA (multiple ligation-dependent probe amplification) or array CGH is now more widely used. MLPA analyzes the copy number of each exon of the STS gene and can detect not only large deletions but also small deletions and exon deletions caused by some point mutations. In about 10-15% of patients in whom no large deletion is identified, point mutations are sought by full-length sequencing of the STS gene (Sanger or NGS-based). Histological examination of a skin biopsy is not specific for X-linked ichthyosis and is mainly used to differentiate it from other forms of ichthyosis. Abnormal granules within the stratum corneum may be observed on electron microscopy.
There is currently no clinically applicable curative (causal) treatment for X-linked ichthyosis, and the goals of treatment are reducing scaling, moisturizing the skin, relieving pruritus, and improving quality of life. Treatment centers on topical therapy, and systemic therapy is considered in moderate or worse cases.
Topical moisturizing treatment is the basis of routine skin care; immediately after bathing or showering, before the water is completely removed, a thick cream or ointment (petroleum jelly, urea-containing cream, etc.) is applied to lock in moisture and minimize transepidermal water loss. Keratolytic agents are effective in reducing scaling, and the main agents are as follows: ① urea-containing preparations (5-40% concentration), ② salicylic acid (2-6%), ③ alpha-hydroxy acids (lactic acid, glycolic acid, etc., 5-12%), ④ propylene glycol mixed with water and applied by the occlusive method can enhance the keratolytic effect. Application frequency is generally 1-2 times/day, with high-concentration keratolytic agents on the trunk and limbs and low-irritation moisturizers on the face and skin folds. Systemic retinoids are considered in moderate or worse X-linked ichthyosis. Acitretin (0.3-0.5 mg/kg/day) is the most studied agent and has the effect of normalizing keratinization and markedly reducing scaling. However, because of adverse effects such as teratogenicity, hepatotoxicity, hyperlipidemia, and mucosal dryness, it is contraindicated in women of childbearing potential, and long-term use in children should be decided carefully considering the risk of growth plate abnormalities. Corneal opacity mostly does not affect vision and does not require treatment, but ophthalmic follow-up at 6-12 month intervals is recommended. When accompanied by Kallmann syndrome, testosterone replacement therapy or gonadotropin therapy for hypogonadism is needed.
X-linked ichthyosis has no directly life-threatening complications, and a normal lifespan can be expected in most patients. However, skin symptoms follow a chronic course persisting throughout life, and complete remission is rare.
Skin symptoms tend to change with age. They are relatively mild in childhood but tend to increase and thicken after puberty under the influence of androgens. A seasonal variation is characteristic, in which scaling temporarily improves in hot summers because of sweat secretion and worsens in cold seasons. With consistent active moisturizing and keratolytic treatment, symptoms can often be controlled to a level that does not interfere with everyday social life and work. The incidence of corneal opacity increases over time, and corneal opacity can be found even in female carriers after middle age. In typical X-linked ichthyosis without neighboring gene deletion, intellectual development, reproductive function, and general health are normal. When the KAL1 gene is included in a contiguous gene deletion, hypogonadism and infertility due to Kallmann syndrome affect the prognosis. Psychosocially, reduced self-esteem, social withdrawal, and anxiety due to the cosmetic skin abnormality can affect quality of life, so psychological support is needed. Preclinical research on gene therapy (delivery of the STS gene via viral vectors) is under way, and the possibility of a fundamental treatment in the future is being explored.
X-linked ichthyosis is a hereditary disease, and preventing its onset itself is not currently possible. Prevention strategies focus on family planning through genetic counseling, prenatal diagnosis for female carriers, and prevention of complications through active skin care.
Genetic counseling must be provided to confirmed patients and their families. The X-linked recessive inheritance pattern is explained, and they are counseled that the probability of a carrier woman's son being affected is 50%. They are also informed that a carrier woman can transmit the disease to her sons even if she herself shows no clinical symptoms, and that corneal opacity may occur. Carrier testing is offered to maternal female relatives such as the patient's mother, sisters, and maternal aunts, and consists of measurement of STS enzyme activity (about 50% reduction in carriers) or molecular genetic testing (confirmation of a heterozygous deletion by MLPA/FISH). Prenatal diagnosis can be performed on request when a carrier woman is pregnant. STS deletion is detected using fetal cell DNA through chorionic villus sampling (CVS) at 10-12 weeks of gestation or amniocentesis at 15-20 weeks. Preimplantation genetic testing (PGT) is a method of selecting STS-deletion-free embryos during in vitro fertilization and can be presented as an option to couples who wish it. For prevention of skin complications, consistent moisturizing and keratolytic treatment should be started early, and patients are educated to avoid harsh cleansers, hot water, and excessive sun exposure that can damage the skin. Regular ophthalmic examinations are recommended, and there is currently no means of preventing corneal opacity itself. Advances in STS gene editing technology are expected to offer a new paradigm for prevention or treatment in the future.